BioCentury
ARTICLE | Top Story

Vertex, CRISPR enter research partnership

October 27, 2015 12:02 AM UTC

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and CRISPR Therapeutics AG (Basel, Switzerland) entered a four-year research collaboration to discover and develop treatments using CRISPR's gene editing technology.

The partners will focus initially on developing cystic fibrosis (CF) therapies that correct mutations in the CF transmembrane conductance regulator ( CFTR) gene. Vertex and CRISPR will also develop treatments for hemoglobinopathies, including sickle cell disease, and evaluate other undisclosed targets under the deal. ...